Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about acid sphingomyelinase: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| NLRP3 | regulates | gene | 0.80 |
| NLRP3 | activates | gene | 0.80 |
| NLRP3 inflammasome | activates | complex | 0.80 |
| NLRP3 inflammasome activation | regulates | pathway | 0.60 |
| Ceramide signaling | involved_in | pathway | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| h-de0d4364 | targets | hypothesis | 0.80 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Selective Acid Sphingomyelinase Modulation Therapy | 0.920 | neurodegeneration | Lipid raft composition changes in synapt |
| SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduct | 0.732 | neurodegeneration | How do sphingomyelin/ceramide ratios spe |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468] | ["Hsu-Heng Lin", "Hui-An Chen", "Shyh-Je | Molecular genetics & genom | 2026 | 0 |
| Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] | ["Aron Park", "Baeki E Kang", "Eun-Ju Ji | Genes & genomics | 2026 | 0 |
| Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenua [PMID:41754105] | Go Y, Joung H, Han SY, Chung J | Nutrients | 2026 | 0 |
| SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immuno [PMID:41795144] | Xu Y, Liu X, Xu B, Li Q, Zhang L, Li C, | CNS neuroscience & therapeutic | 2026 | 0 |
| A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606] | Yu X MD, Lei J MSc, Du X MSc, He Y MSc, | Int J Surg | 2026 | 0 |
| Plasma metabolites may inhibit childhood obesity by regulating ferroptosis throu [PMID:41249848] | Wang JG, Pan XH, Li Y | Int J Obes (Lond) | 2026 | 0 |
| Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] | Park A, Kang BE, Jin EJ, Kim HJ, Lee CW | Genes Genomics | 2026 | 0 |
| AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160] | Jia J, Gan Y, Li J, Li L, Meng H et al. | Adv Sci (Weinh) | 2026 | 0 |
| Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468] | Lin HH, Chen HA, Lin SJ, Hsu RH, Lee NC | Mol Genet Genomic Med | 2026 | 0 |
| Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Ant [PMID:41824764] | Liu H, Aili A, Kuang Z, Cao L, Li Z, Sha | Advanced science (Weinheim, Ba | 2026 | 0 |
| Suspected Niemann-Pick disease type B with sea-blue histiocytosis after splenect [PMID:41791926] | Liu W, Qin L, Wang G | Journal of clinical lipidology | 2026 | 0 |
| Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt [PMID:41716780] | Arafa NA, Mahfouz A, Anwar S, Marzouk I | Molecular genetics and metabol | 2026 | 0 |
| AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160] | Jia J, Gan Y, Li J, Li L, Meng H, Sun M, | Advanced science (Weinheim, Ba | 2026 | 0 |
| A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606] | Yu X, Lei J, Du X, He Y, Peng W, Yang R, | International journal of surge | 2026 | 0 |
| Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment s [PMID:39825014] | Chestnykh D, Mühle C, Schumacher F, Kali | Mol Psychiatry | 2025 | 0 |
| Reduction of sphingomyelinase activity associated with progranulin deficiency an [PMID:40633679] | Boyle NR, Fox SN, Tadepalli AS, Seyfried | Neurobiol Dis | 2025 | 0 |
| Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment s [PMID:39825014] | Chestnykh D, Mühle C, Schumacher F, Kali | Molecular psychiatry | 2025 | 0 |
| Reduction of sphingomyelinase activity associated with progranulin deficiency an [PMID:40633679] | Boyle NR, Fox SN, Tadepalli AS, Seyfried | Neurobiology of disease | 2025 | 0 |
| Acid sphingomyelinase as a pathological and therapeutic target in neurological d [PMID:38337058] | Choi BJ, Park MH, Jin HK, Bae JS | Exp Mol Med | 2024 | 0 |
| Acid sphingomyelinase as a pathological and therapeutic target in neurological d [PMID:38337058] | Choi BJ, Park MH, Jin HK, Bae JS | Experimental & molecular medic | 2024 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning acid sphingomyelinase in their description or question text
No additional research found